Pfizer and Lilly announce tanezumab BLA accepted

2 March 2020

The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for tanezumab 2.5mg administered subcutaneously (SC) for patients with chronic pain due to moderate-to-severe osteoarthritis (OA), who have experienced inadequate relief with other analgesics.

Tanezumab is a monoclonal antibody being developed by US pharma companies Pfizer (NYSE: LLY) and Eli Lilly (NYSE: LLY) that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor inhibitors.

PDUFA of December this year

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology